{"id":760223,"date":"2023-05-24T08:05:15","date_gmt":"2023-05-24T12:05:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/"},"modified":"2023-05-24T08:05:15","modified_gmt":"2023-05-24T12:05:15","slug":"enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/","title":{"rendered":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug"},"content":{"rendered":"

<\/p>\n

Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug<\/b><\/p>\n

New composition of matter claims expands intellectual property for Enveric\u2019s EVM201 Series<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Enveric Biosciences, Inc.<\/a> (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series. This is the second Notice of Allowance from the USPTO for intellectual property governing the EVM201 Series. Notices of Allowance are issued by the USPTO after it has made a determination that a patent should be granted from an application.<\/p>\n

\nThe soon-to-issue patent, titled, \u201cC4-Carboxylic Acid-Substituted Tryptamine Derivatives and Methods of Using,\u201d contains composition of matter claims for a family of novel prodrug derivatives of psilocin that is structurally different from the recently announced Notice of Allowance for C4-carbonothioate-substituted tryptamine derivatives. Collectively, it is expected that the two patent families will provide Enveric with a robust intellectual property portfolio governing psilocin prodrugs designed to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin.<\/p>\n

\n\u201cThis latest Notice of Allowance related to our EVM201 Series highlights the unique psilocin prodrug designs being developed by our R&D team, which are differentiated from other psilocybin-assisted therapies in both design and expected function,\u201d said Joseph Tucker, Ph.D., Director and CEO of Enveric. \u201cSecuring intellectual property to protect our technological advances is a critical component to our growth strategy, and we anticipate multiple additional claims in the coming months for both our EVM201 and EVM301 Series.\u201d<\/p>\n

\nIn addition to the two EVM201 Series-focused Notices of Allowance, Enveric has filed 10 distinct patent families to date protecting its EVM301 Series. Enveric\u2019s EVM301 Series of small molecule therapies are specifically designed to promote neuroplasticity and show efficacy in animal models of depression and anxiety without inducing the hallmark hallucinations of other psychedelic or psychedelic-inspired agents.<\/p>\n

About Enveric Biosciences<\/b><\/p>\n

\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary\u2122, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric\u2019s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series \u2013 EB-373 \u2013 for the treatment of anxiety disorders. Enveric is also advancing its second program, the EVM301 Series, to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as \u201cplans,\u201d expects\u201d or \u201cdoes not expect,\u201d \u201cproposed,\u201d \u201cis expected,\u201d \u201cbudgets,\u201d \u201cscheduled,\u201d \u201cestimates,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201canticipates\u201d or \u201cdoes not anticipate,\u201d or \u201cbelieves,\u201d or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: carry out successful clinical programs in Australia; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric\u2019s products, including patent protection; identify and pursue alternative routes to capture value from its cannabinoid clinical development pipeline assets; continue as a going concern; manage its future growth effectively; achieve the intended benefits of the cost reduction plan to the extent or as quickly as anticipated\u037e transition from third-party service providers supporting R&D efforts to internal science teams without any adverse impact on Enveric\u2019s ongoing and planned clinical trials; and engage the cost reduction plan efforts without negatively impacting Enveric\u2019s business operations and reputation.<\/p>\n

\nA discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission (SEC), including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230524005413\/en\/<\/a><\/span><\/p>\n

Investor Relations
\n<\/b>
Tiberend Strategic Advisors, Inc.
\n<\/a>
Daniel Kontoh-Boateng
\n
(862) 213-1398
\n
dboateng@tiberend.com<\/a><\/p>\n

Media Relations
\n<\/b>
Tiberend Strategic Advisors, Inc.
\n<\/a>
Casey McDonald
\n
(646) 577-8520
\n
cmcdonald@tiberend.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Florida Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Mental Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expands intellectual property for Enveric\u2019s EVM201 Series CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series. This is the second Notice of Allowance from the USPTO for intellectual property governing the EVM201 Series. Notices of Allowance are issued by the USPTO after it has made a determination that … <\/p>\n

Continue reading “Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760223","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expands intellectual property for Enveric\u2019s EVM201 Series CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series. This is the second Notice of Allowance from the USPTO for intellectual property governing the EVM201 Series. Notices of Allowance are issued by the USPTO after it has made a determination that … Continue reading "Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-24T12:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug\",\"datePublished\":\"2023-05-24T12:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/\"},\"wordCount\":1012,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/\",\"name\":\"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-24T12:05:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk","og_description":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expands intellectual property for Enveric\u2019s EVM201 Series CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series. This is the second Notice of Allowance from the USPTO for intellectual property governing the EVM201 Series. Notices of Allowance are issued by the USPTO after it has made a determination that … Continue reading \"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-24T12:05:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug","datePublished":"2023-05-24T12:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/"},"wordCount":1012,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/","name":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-24T12:05:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230524005413r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760223"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}